Aikium is Unlocking the Undruggable Proteome
Using the Worlds First AI-Powered Trillion-Molecule Screening
Yotta-ML²: Where AI Meets the Proteome
Screening AI-designed ultra-large libraries with unprecedented precision
Unmatched Scale: 1,000x library capacity vs. traditional methods
Target-Agnostic: From G protein-coupled receptors (GPCRs) to Ion Channels and beyond
Rapid Development: Achieving therapeutic breakthroughs in months, not years
Yotta-ML2
Yotta-ML2 the platform that enables Yotta-scale (1024) machine learning (ML) on massive libraries by combining the world’s only AI-Driven trillion-protein mRNA display for large proteins and patented generative AI based on protein language models
Deep Learning Engine
1011
Synthetic Biology Platform
1013
Proprietary Models
Latest News
November 2024
Why we are Different
Binders to Differentiated Regions: Targeting areas antibodies and small molecules cannot
High-Impact Partnerships: Collaborating with leading pharma and academic institutions
Proven Team: Leaders from NVIDIA, Harvard, 10X Genomics, NIH and the Wyss Institute
Advisory Board
-
Dr. Kevin Yang
DEEP LEARNING FOR PROTEINS EXPERT
Microsoft Research
-
Dr. Leena Das-Young
CEO Caliber Bio, Ex-Pfizer
-
Dr. Nina Bhardwaj
Mt. Sinai, New York
-
Dr. Tracy Handel
Univ. of California, San Diego
-
Prof. George Church
Harvard, MIT, Wyss
-
Dr. Mark Lebwohl
Mt. Sinai, New York
-
Dr. Nicolas Gaudenzio
INSERM, Genoskin
-
Prof. Lawrence Stern
U Mass Med School, MIT
-
Dr. Mette Rosenkilde
Univ. of Copenhagen, Bainan, Synklino, Antag Tx
-
Dr. Tarjei Mikkelsen
CTO, Arsenal Bio
Founders
Investors
Aikium is Calling!
Join the foundational team pioneering a transformative platform with the power to shape the future of medicine. Together, we aim to deliver 100 breakthrough therapies within the next decade.
